An international team of investigators assessed the ability of flutemetamol F 18-labeled PET and other biomarkers to predict risk of clinical progression from amnestic mild cognitive impairment to probable Alzheimer disease.
An international team of investigators assessed the ability of flutemetamol F 18-labeled PET and other biomarkers to predict risk of clinical progression from amnestic mild cognitive impairment to probable Alzheimer disease.